Vericiguat Registry
Not Applicable
Recruiting
- Conditions
- Chronic heart failure with reduced ejection fraction(HFrEF)
- Registration Number
- JPRN-UMIN000046870
- Lead Sponsor
- Okayama university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Women who are pregnant or may become pregnant (2) Patients with a history of hypersensitivity to Vericiguat (3) Patients receiving soluble guanylate cyclase (sGC) stimulator (riociguat) 3) Patients receiving soluble guanylate cyclase (sGC) stimulant (riociguat). 4) Other patients who are deemed unsuitable for this study by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Right heart function indices by echocardiography at 24 weeks (RVFAC, RV diameter (base, mid, longitudinal), RV thickness, RV s', TAPSE)
- Secondary Outcome Measures
Name Time Method TproBNP (12 weeks, 24 weeks) High-sensitivity troponin T (12 weeks, 24 weeks) KCCQ (12 weeks, 24 weeks) NYHA (12 weeks, 24 weeks) Echocardiographic indices Vericiguat dose (12 weeks, 24 weeks, 1 year) Clinical outcomes (death, cardiovascular death, hospitalization for worsening heart failure) Incidence of adverse events